2026-01-18 - Analysis Report
**Company Overview**
Abbott Laboratories (ABT) is a diversified healthcare company

**Cumulative Return Comparison**
| Stock | Cumulative Return |
| --- | --- |
| ABT | 32.54% |
| VOO | 93.36% |
_Degree of Divergence_: -60.80

**Alpha, Beta Analysis**
| Period | CAGR | MDD  | Alpha | Beta | Market Cap (B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 32.0% | 14.5% | 29.0% | 1.1 | 125.9 |
| 2017-2019 | 41.0% | 14.5% | 24.0% | 1.0 | 151.2 |
| 2018-2020 | -1.0% | 16.8% | -22.0% | 0.9 | 190.6 |
| 2019-2021 | 42.0% | 16.8% | -2.0% | 0.8 | 244.9 |
| 2020-2022 | -20.0% | 28.8% | -18.0% | 0.8 | 191.1 |
| 2021-2023 | -22.0% | 28.8% | -23.0% | 0.7 | 191.6 |
| 2022-2024 | -31.0% | 24.3% | -50.0% | 0.7 | 196.9 |
| 2023-2025 | 10.0% | 16.0% | -52.0% | 0.3 | 218.1 |

**Recent Stock Price Fluctuations**
|  | Value |
| --- | --- |
| Close | $121.76 |
| Last-market | $121.76 ($123.53 -1.43%) |
| 5-day SMA | $123.85 |
| 20-day SMA | $125.12 |
| 60-day SMA | $125.91 |

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence, Expected_Return**
| Indicator | Value |
| --- | --- |
| RSI | 39.06 |
| PPO | -0.24 |
| Hybrid Signal | Buy (Cash 0%) |
| Recent relative divergence change | -2.00 (-) |
| 7-day Rank change | 0 (0) |
| 7-day Dynamic Expected Return change | 0.00 (0) |
| Expected Return (%) | -1612.30% |

**Recent News & Significant Events**
* [2026-01-06] PBH vs. ABT: Which Stock Is the Better Value Option? - Yahoo Finance
* [2026-01-16] Fund Update: New $84.6M $ABT stock position opened by Compagnie Lombard Odier SCmA - Quiver Quantitative
* [2026-01-17] Abbott Laboratories (NYSE:ABT) Stands Out as a Dependable Dividend Stock for Income Investors - Chartmill
* [2026-01-05] How to listen as Abbott breaks down its latest quarterly results Jan. 22 - Stock Titan
* [2026-01-16] Absolute Software Co. (ABT.TO) (TSE:ABT) Stock Crosses Above Two Hundred Day Moving Average - Here's Why - MarketBeat
* [2025-12-12] Investors - Abbott

**Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.71 (~Buy)
- Opinions: 25
- Target Price (avg/high/low): $144.75 / $169.00 / $122.00

**Recent Earnings Analysis**
| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-29 | $0.94 | $11.37B |
| 2025-07-30 | $1.02 | $11.14B |
| 2025-04-30 | $0.76 | $10.36B |
| 2024-10-31 | $0.94 | $10.63B |

**Financial Information: Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |
| 2024-09-30 | $10.63B | 55.83% |

**Financial Information: Capital and Profitability**
| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |
| 2024-09-30 | $39.80B | 4.14% |

**Comprehensive Analysis**
Based on the analysis of the provided data, Abbott Laboratories is showing a relatively low cumulative return rate compared to the S&P 500. The Alpha, Beta analysis displays a generally declining trend in stock performance with some periods showing positive growth. Recent stock price fluctuations indicate a slight decline in the 5-day SMA and a steady increase in the 20-day SMA and 60-day SMA. The RSI, PPO Index Indicators, and Delta_Previous_Relative_Divergence, Expected_Return suggest a bearish trend in the stock's performance. Recent news and significant events point to various updates and ratings on the company stock. Analyst opinions are overall positive, recommending a "Buy" and a target price of $144.75. The recent earnings analysis displays fluctuations in EPS and revenue. Financial information and profitability data show variations in revenue and profit margin. Overall, Abbott Laboratories presents a complex financial situation, requiring further examination to determine its long-term potential for investment.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.